Archives
-
Rimonabant and the Next Wave of CB1 Research
2026-09-28
Rimonabant (SR141716) remains a powerful CB1 pathway probe for appetite regulation research, obesity research, inflammation, and neurobiology. This thought-leadership analysis connects its receptor selectivity with emerging evidence that Cannabis terpenes produce antinociception through adenosine A2A receptors, offering translational researchers a framework for separating cannabinoid signaling from parallel mechanisms.
-
ANGPTL3 CRISPR Multiplexing: R2999 Guide Overview
2026-09-28
The R2999 dossier describes three sgRNAs targeting human ANGPTL3, with 3 µmol of each guide listed; it does not provide sequences or editing-performance data. Multiplexed CRISPR can target multiple genomic sites, but guide identity, Cas system, delivery, and validation determine what the experiment can establish.
-
Multiplexed CRISPR–Cas for Genome Engineering
2026-09-27
This 2025 review explains how multiple guide RNAs can extend CRISPR–Cas from single-site editing to large deletions, structural-variant engineering, coordinated gene regulation, and selective cell killing. It emphasizes that multiplexing expands experimental capability while making guide design, outcome validation, and the cellular consequences of simultaneous DNA breaks central considerations.
-
TMRE C8197: Mitochondrial Potential in Context
2026-09-26
Tetramethylrhodamine ethyl ester perchlorate (TMRE) reports mitochondrial membrane potential in living cells, but a fluorescence change is not a complete explanation of oxidative injury. This article shows how to interpret TMRE alongside mechanistic evidence on caspase-3, complex I, and ER-derived ROS in trichothecene research.
-
BEND Lipids Improve mRNA and RNP Delivery
2026-09-25
The study introduces branched endosomal disruptor (BEND) ionizable lipids and reports improved delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes in hepatic gene-editing and T-cell engineering settings. Its central implication is that terminal branching can alter endosomal interactions and improve functional delivery, although performance remains dependent on the formulation and biological context.
-
Doxycycline Hyclate for BBB Mechanism Studies
2026-09-25
Explore how Doxycycline hyclate can help test links between MMP activity, blood–brain barrier integrity, and neuronal injury. This article turns a mouse arsenic study into a cautious, endpoint-driven framework for interpreting matrix metalloproteinases inhibitor experiments.
-
From RNA Signal to Translation: Better Delivery Readouts
2026-09-24
Translational mRNA research needs to distinguish cellular association from productive protein expression. This article explains how dual-fluorescence measurements, careful controls, and evidence-aware assay design can strengthen delivery-system decisions, with ARCA Cy5 EGFP mRNA (5-moUTP) as a practical research tool.
-
Dual TLR2/4 Inhibition in Oxygen-Induced Retinopathy
2026-09-24
Dayoub et al. evaluated AVR-121 and AVR-123, small molecules that inhibit both TLR2 and TLR4, across immune-cell, retinal endothelial-cell, and mouse oxygen-induced retinopathy models. Their findings support investigating stage-specific inflammatory signaling as a way to reduce retinal vascular injury and abnormal neovascularization, while emphasizing that the compounds are not selective TLR4 inhibitors and the results do not establish clinical efficacy.
-
Rocilinostat: Selective HDAC6 Inhibition in Translation
2026-09-23
Rocilinostat (ACY-1215) gives translational researchers a selective way to probe HDAC6 biology, from α-tubulin acetylation to proteasome-inhibitor combinations in multiple myeloma models. This article connects mechanism to experimental design while clarifying the evidence boundaries.
-
Using (R)-MG132 for Proteasome Assay Rigor
2026-09-23
(R)-MG132 is a functionally inactive MG-132 enantiomer designed to expose nonspecific effects that can be mistaken for proteasome inhibition. This guide shows how to pair it with active inhibitor conditions, cell-based assays, and mechanistic studies of cancer metabolism for more defensible conclusions.
-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-09-22
The reference study identifies an epigenetic mechanism by which EBV latent membrane protein 1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It further shows that HDAC inhibition can restore CEBPA expression and partially reverse this state, providing a mechanistic basis for differentiation-oriented treatment strategies in solid tumors.
-
Mithramycin A: Mechanism and Research Use
2026-09-22
Mithramycin A is an anticancer antibiotic that binds G-C-rich DNA in the presence of divalent metal ions and suppresses transcription-related processes. Its reported c-myc regulation and HL-60 differentiation effects support focused leukemia research and cancer biology research, but the compound is intended for scientific research use only.
-
Tirbanibulin Rewires HPV-Linked Oncogenic Signaling
2026-09-21
A 2024 study in HeLa cells shows that tirbanibulin suppresses proliferation at nanomolar concentrations while reducing HPV-18 oncoproteins and multiple Src-linked signaling proteins. The findings connect tirbanibulin’s established antiproliferative activity with altered cell-cycle, invasion, translation, and apoptosis-associated protein expression, although the mechanism remains primarily correlative and requires validation beyond this cell model.
-
Dual TLR2/4 Inhibition in Oxygen-Induced Retinopathy
2026-09-21
The reference study identifies AVR-121 and AVR-123 as dual TLR2/4 inhibitors that suppress inflammatory and pathological angiogenic responses associated with oxygen-induced retinopathy. Its strongest contribution is the in vivo demonstration that AVR-123 can reduce vaso-obliteration, neovascularization, and inflammatory cytokine changes while preserving the physiological VEGF response in juvenile mouse eyes.
-
Topotecan B4982: Reproducible Cytotoxicity Assays
2026-09-20
A scenario-based guide to using Topotecan (SKU B4982) in viability, proliferation, apoptosis, and drug-resistance studies. It connects mechanism, formulation, concentration selection, ABCG2 biology, and vendor evaluation to practical cancer research workflows.